Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 16Recurrence 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Breast Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

Dexamethasone 6Calcium Dobesilate 3Lenalidomide 2Cyclophosphamide 2venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1belantamab mafodotin 1auricularum 1Thalidomide 1Melphalan 1Lisaftoclax 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1GTP Cyclohydrolase 1Drug Evaluation 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Amyloidosis × ixazomib × Clear all
NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Mayo Clinic

Phase 1/2 Completed
87 enrolled 13 charts
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡